RxDoctor Payments Data

Eva Magiros, MD

Cardiovascular Disease · Biloxi, MSNPI 1033168091

Payments from drug & device makers

$2,139in general payments, 2019–2025

Across 137 payments — averaging $15.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$515
  • Merck$460
  • Pfizer$281
  • Johnson & Johnson$179
  • Abbott$154
  • Amgen$129
  • plus $422 from 11 others

What the payments were for

  • Food & beverage$2,139100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,139 in reported general payments places this provider in the 30th percentile of 144 cardiovascular disease providers in Mississippi.

See all cardiovascular disease providers in Mississippi

Medicare billing

Part B allowed, 2024
$97,740
Medicare patients
459
Services billed
1,250

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban241$226,852
XareltoRivaroxaban129$141,307
EntrestoSacubitril/Valsartan89$89,871
Repatha SureclickEvolocumab36$36,920
BrilintaTicagrelor20$20,493
FarxigaDapagliflozin Propanediol19$17,019
Praluent PenAlirocumab19$16,191
NexlizetBempedoic Acid/Ezetimibe18$11,003
NexletolBempedoic Acid11$8,795
Valsartan114$4,165
ClopidogrelClopidogrel Bisulfate259$3,047
Amiodarone Hcl154$2,975
Propafenone Hcl50$2,519
Potassium Chloride139$2,507
Metoprolol Succinate185$2,412

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$281$226,852241 claims
Johnson & JohnsonXarelto$179$141,307129 claims
NovartisEntresto$515$89,87189 claims
AstraZenecaBrilinta, Farxiga$15$37,51239 claims
Esperion Therapeutics, Inc.Nexlizet, Nexletol$94$19,79829 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 144 cardiovascular disease providers in Mississippi.

Other cardiovascular disease in Biloxi

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →